ipilimumab,nivolumab
bms
[]
#gi23 presented the 29 month follow up of checkmate 648 showing a continued improvement in mos with the addition of nivo to cis/5fu for patients with esophageal squamous cell cancer 
GI Onc at Hopkins, focusing on #PancreaticCancer, #PrecisionMedicine. Striving to improve patient outcomes.
Originator of #TumorBoardTuesday @TumorBoardTues